» Articles » PMID: 35707536

Interplay Between Solid Tumors and Tumor Microenvironment

Overview
Journal Front Immunol
Date 2022 Jun 16
PMID 35707536
Authors
Affiliations
Soon will be listed here.
Abstract

Over the past few decades, basic studies aimed at curing patients with cancer have been constantly evolving. A myriad of mechanistic studies on physiological changes and related factors in tumor growth and metastasis have been reported. Recently, several studies have been considerate to how tumors adapt to unfavorable environments, such as glucose deprivation, oxidative stress, hypoxic conditions, and immune responses. Tumors attempt to adapt to unfavorable environments with genetic or non-genetic changes, the alteration of metabolic signals, or the reconfiguration of their environment through migration to other organs. One of the distinct features in solid tumors is heterogeneity because their environments vary due to the characteristics of colony growth. For this reason, researchers are paying attention to the communication between growing tumors and neighboring environments, including stromal cells, immune cells, fibroblasts, and secreted molecules, such as proteins and RNAs. During cancer survival and progression, tumor cells undergo phenotype and molecular changes collectively referred to as cellular plasticity, which result from microenvironment signals, genetics and epigenetic alterations thereby contributing to tumor heterogeneity and therapy response. In this review, we herein discuss the adaptation process of tumors to adverse environments communication with neighboring cells for overcoming unfavorable growth conditions. Understanding the physiology of these tumors and their communication with the tumor environment can help to develop promising tumor treatment strategies.

Citing Articles

From multi-omics to predictive biomarker: AI in tumor microenvironment.

Hai L, Jiang Z, Zhang H, Sun Y Front Immunol. 2025; 15:1514977.

PMID: 39763649 PMC: 11701166. DOI: 10.3389/fimmu.2024.1514977.


Exosomal circular RNAs in tumor microenvironment: An emphasis on signaling pathways and clinical opportunities.

Li J, Zhou W, Wang H, Huang M, Deng H MedComm (2020). 2024; 5(12):e70019.

PMID: 39584047 PMC: 11586091. DOI: 10.1002/mco2.70019.


Bladder Cancer Treatments in the Age of Personalized Medicine: A Comprehensive Review of Potential Radiosensitivity Biomarkers.

Feghaly C, Challita R, Hadir H, Mobayed T, Bitar T, Harbi M Biomark Insights. 2024; 19:11772719241297168.

PMID: 39512649 PMC: 11542137. DOI: 10.1177/11772719241297168.


Beyond aromatherapy: can essential oil loaded nanocarriers revolutionize cancer treatment?.

Alabrahim O, Lababidi J, Fritzsche W, Azzazy H Nanoscale Adv. 2024; .

PMID: 39415775 PMC: 11474398. DOI: 10.1039/d4na00678j.


Decoding the Role of Insulin-like Growth Factor 1 and Its Isoforms in Breast Cancer.

Kotsifaki A, Maroulaki S, Karalexis E, Stathaki M, Armakolas A Int J Mol Sci. 2024; 25(17).

PMID: 39273251 PMC: 11394947. DOI: 10.3390/ijms25179302.


References
1.
Sharonov G, Serebrovskaya E, Yuzhakova D, Britanova O, Chudakov D . B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat Rev Immunol. 2020; 20(5):294-307. DOI: 10.1038/s41577-019-0257-x. View

2.
Reina-Campos M, Moscat J, Diaz-Meco M . Metabolism shapes the tumor microenvironment. Curr Opin Cell Biol. 2017; 48:47-53. PMC: 5650101. DOI: 10.1016/j.ceb.2017.05.006. View

3.
Jing Y, Han Z, Zhang S, Liu Y, Wei L . Epithelial-Mesenchymal Transition in tumor microenvironment. Cell Biosci. 2011; 1:29. PMC: 3179439. DOI: 10.1186/2045-3701-1-29. View

4.
Paolillo M, Schinelli S . Integrins and Exosomes, a Dangerous Liaison in Cancer Progression. Cancers (Basel). 2017; 9(8). PMC: 5575598. DOI: 10.3390/cancers9080095. View

5.
Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S . NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity. 2018; 48(2):396-398. PMC: 5823842. DOI: 10.1016/j.immuni.2018.01.010. View